Servier shared on X:
“In 2025, bispecific antibodies are standing out for their ability to target two disease markers at once, boosting the effectiveness of cancer treatments.
At the same time, antibody-drug conjugates (ADCs) are delivering medicine straight inside cancer cells, reducing side effects for patients.
What is the main characteristic of monoclonal antibodies?”
More about ADCs.